Taurohyocholate, taurocholate, and tauroursodeoxycholate but not tauroursocholate and taurodehydrocholate counteract effects of taurolithocholate in rat liver.
The infusion of taurolithocholate (TLC) in vivo or in the isolated perfused liver of the rat causes cholestasis and cellular necrosis. In order to analyze the protective effect of bile salts differing in number and steric position of their hydroxy groups against TLC-induced cholestasis, isolated rat livers were perfused with taurocholate (TC), taurohyocholate (THC), tauroursocholate (TUC), taurodehydrocholate (TDHC), and tauroursodeoxycholate (TUDC) (16 and 32 mumol/l) with or without TLC (8 and 16 mumol/l). Bile flow, bile salt secretion, and the hydroxylation pattern of the bile salts secreted were analyzed. TLC caused complete cholestasis after 15 min of perfusion. All bile salts studied had a protective effect. THC, TC, and TUDC completely abolished the cholestasis induced by TLC while TUC did so only for the first 10 min. TDHC was protective only as long as it was biotransformed into hydroxyoxo bile salts. Coinfusion of bile salts did not influence uptake of TLC (greater than or equal to 93% of dose). Differences were found regarding the amount of TLC biotransformed (% of uptake): TC 50%; THC 32%; TUDC 36%; TUC 20%. Light microscopy revealed cellular necrosis, and dilated canaliculi were found in livers perfused with TLC only or in combination with TUC or TDHC, while the other bile salts prevented these changes. We conclude that bile salts with low micelle-forming capacity have little protective effect against TLC-induced cholestasis. These bile salts induce less biotransformation of TLC than TC, THC, and TUDC. The protective effect is not dependent on the hydrocholeretic effect of the added bile salt and is not due to an uptake inhibition.
Schölmerich
J
J
Dept. of Internal Medicine, University of Freiburg, Federal Republic of Germany.
Kitamura
S
S
Baumgartner
U
U
Miyai
K
K
Gerok
W
W
D000818:Animals; D001647:Bile Acids and Salts / Q000494:pharmacology / Q000627:therapeutic use*; D001711:Biotransformation; D002779:Cholestasis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D066298:In Vitro Techniques; D008095:Lithocholic Acid / Q000031:analogs & derivatives*; D008297:Male; D051381:Rats; D013658:Taurolithocholic Acid / Q000493:pharmacokinetics / Q000633:toxicity*
D001647:Bile Acids and Salts; D013658:Taurolithocholic Acid; D008095:Lithocholic Acid